Amorphous calcium carbonate supplementation and bone outcomes in rheumatoid arthritis: A prospective cohort study - PubMed
4 days ago
- #osteoporosis
- #rheumatoid-arthritis
- #bone-health
- Rheumatoid arthritis (RA) increases the risk of osteoporosis and fractures.
- Amorphous calcium carbonate (ACC) supplementation may improve bone mineral density (BMD) and osteogenic differentiation.
- A study of 67 RA patients with osteopenia/osteoporosis showed ACC (800 mg/day calcium + 400 IU/day vitamin D3) increased femoral neck BMD after 12 months.
- ACC supplementation also reduced bone turnover markers (N-terminal propeptide of type I collagen and C-terminal cross-linking telopeptide).
- Age and corticosteroid use (≥5 mg) were significant risk factors for major osteoporotic fractures.
- RA disease activity scores inversely correlated with femoral neck BMD.
- ACC benefits were more pronounced in anti-citrullinated peptide antibody-positive patients.